Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -25.80 -1.74% 1,457.80 1,457.60 1,458.00 1,484.20 1,455.40 1,478.60 12,816,995 16:29:59
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 34,114.0 5,442.0 87.6 16.6 59,294

GSK Says FDA Accepts Momelotinib's New Drug Application

17/08/2022 7:46am

Dow Jones News

Historical Stock Chart

From Jun 2022 to Dec 2022

Click Here for more Gsk Charts.

By Anthony O. Goriainoff


GSK PLC said Wednesday that momelotinib's new drug application, or NDA, has been accepted by the U.S. Food and Drug Administration for the treatment of myelofibrosis.

The U.K. pharmaceutical company said the FDA assigned a Prescription Drug User Fee Act, or PDUFA, action date of June 16, 2023.

The PDUFA refers to the date by which the agency's review process must be completed.

The FTSE 100-listed company said the NDA is based on results from key Phase 3 trials which met all primary and key secondary endpoints, and added that momelotinib wasn't currently approved in any market.


Write to Anthony O. Goriainoff at


(END) Dow Jones Newswires

August 17, 2022 02:31 ET (06:31 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221209 22:26:08